Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

08 mars 2017 07h00 HE | Source: Trevena Inc.

Trevena Reports Full Year 2016 Earnings

– Two positive Phase 3 pivotal efficacy studies of OLINVO™ (oliceridine injection) completed – – OLINVO program on track for NDA submission in fourth quarter of 2017 – – Company to host conference...
02 mars 2017 07h00 HE | Source: Trevena Inc.

Trevena to Host Conference Call on March 8th to Discuss Full Year 2016 Financial Results

KING OF PRUSSIA, Pa., March 02, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host a conference call on Wednesday, March 8, 2017 at 8:00 am EST to review...
21 févr. 2017 07h00 HE | Source: Trevena Inc.

Trevena Announces Positive Top-line Results from Two Phase 3 Pivotal Efficacy Studies of Intravenous Oliceridine in Moderate-to-Severe Acute Pain

– Program is on track for NDA submission in 4Q 2017 – – OLINVOTM to be the proprietary brand name for oliceridine –– Company to host conference call and webcast at 8:00...
04 janv. 2017 07h00 HE | Source: Trevena Inc.

Trevena Completes Enrollment of Phase 3 APOLLO Pivotal Efficacy Trials of Oliceridine for Moderate-to-Severe Acute Pain

KING OF PRUSSIA, Pa., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it has completed enrollment of its Phase 3 APOLLO-1 and APOLLO-2 pivotal efficacy studies of...